•
Jun 30, 2022
Lyell Immunopharma Q2 2022 Earnings Report
Lyell Immunopharma's financial results for Q2 2022 were reported, and business highlights were discussed.
Key Takeaways
Lyell Immunopharma reported revenue of $35.7 million for the second quarter of 2022, primarily related to the GSK Agreement. The company's cash, cash equivalents, and marketable securities totaled $787.0 million as of June 30, 2022, which is expected to fund operations into 2025.
Revenue was $35.7 million for the three months ended June 30, 2022, primarily related to the GSK Agreement.
Net loss for the second quarter ended June 30, 2022 was $36.3 million.
Cash, cash equivalents and marketable securities as of June 30, 2022 were $787.0 million.
The company believes that its cash, cash equivalents and marketable securities balances will be sufficient to meet working capital and capital expenditure needs into 2025.